Statistical considerations for a trial of Ebola virus disease therapeutics
- 14 January 2016
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 13 (1) , 39-48
- https://doi.org/10.1177/1740774515620145
Abstract
The 2014 West African outbreak of Ebola virus ravaged Liberia, Sierra Leone, and Guinea, causing hemorrhagic fever and death. The need to identify effective therapeutics was acute. The usual drug development paradigm of phase I, followed by phase II, and then phase III trials would take too long. These and other factors led to the design of a clinical trial of Ebola virus disease therapeutics that differs from more conventional clinical trial designs. This article describes the Ebola virus disease medical countermeasures trial design and the thinking behind it.Keywords
This publication has 13 references indexed in Scilit:
- Ebola virus vaccine trials: the ethical mandate for a therapeutic safety netBMJ, 2014
- Ebola vaccine trials raise ethical issuesScience, 2014
- Combining One-Sample Confidence Procedures for Inference in the Two-Sample CaseBiometrics, 2014
- Applicability of sample size calculations based on a comparison of proportions for use with the logrank testControlled Clinical Trials, 1985
- Designs for group sequential testsControlled Clinical Trials, 1984
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983
- Group sequential methods in the design and analysis of clinical trialsBiometrika, 1977
- Repeated assessment of results in clinical trials of cancer treatmentThe British Journal of Radiology, 1971
- Repeated Significance Tests on Accumulating DataJournal of the Royal Statistical Society. Series A (General), 1969
- A New Test for 2 × 2 TablesNature, 1945